文献速递前列腺癌

荧光免疫组化检测PTEN表达缺失预测前列腺切除术后致死性前列腺癌

Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
PubMed 文献 · Eur Urol Oncol · 2018-10-04

本研究利用前列腺切除标本构建组织微阵列,采用双荧光免疫组化(FIHC)定量检测PTEN与AMACR,评估PTEN表达缺失与术后转移和死亡的关系。结果显示低PTEN表达与转移风险升高和总生存期较差独立相关,将PTEN状态加入临床病理因素可增量改善10年预后模型。

要点

  • 低PTEN表达与转移风险升高独立相关,连续变量HR 1.49,二分类变量HR 1.92。
  • 低PTEN表达与总生存期较差独立相关,连续变量HR 1.89,二分类变量HR 2.66。
  • PTEN状态加入年龄、Gleason评分和分期后,10年转移AUC从0.76升至0.80,死亡AUC从0.70升至0.75。

核心结论

  • FIHC检测的原发前列腺癌低PTEN表达是根治性治疗后转移和死亡的独立预后生物标志物。
  • 在此背景下,PTEN的FIHC检测是一种可行的临床诊断方法。

研究设计与样本

  • 使用福尔马林固定石蜡包埋的前列腺根治切除标本构建组织微阵列,进行PTEN和AMACR双荧光免疫组化及半定量多光谱成像分析。
  • 在多变量分析中调整年龄、Gleason评分和分期,评估PTEN状态(连续变量及二分类:低表达为最低四分位数 vs 较高表达为高于最低四分位数)与转移和死亡的关系。
  • 采用逻辑回归模型评估PTEN的预后能力。

主要发现

  • 低PTEN表达与转移风险升高相关:连续变量HR 1.49(95%CI 1.14-1.92;p<0.003),二分类变量HR 1.92(95%CI 1.02-3.63;p=0.04)。
  • 低PTEN表达与总生存期较差显著相关:连续变量HR 1.89(95%CI 1.37-2.63;p<0.001),二分类变量HR 2.66(95%CI 1.34-5.28;p=0.005)。
  • 将PTEN状态加入临床病理因素(年龄、Gleason评分和分期)后,10年转移预后模型的AUC从0.76升至0.80,死亡预后模型的AUC从0.70升至0.75。

临床怎么用

  • 原文结论指出FIHC检测PTEN是此背景下可行的临床诊断方法,低PTEN表达为独立预后生物标志物。
  • 原文患者总结指出评估PTEN状态可能有助于更好地确定不良结局风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PTEN deletion is associated with relapse after therapy for localized prostate cancer. There are limited data on PTEN loss as detected by immunohistochemistry (IHC) and the risk of lethal disease after surgery. OBJECTIVE: To determine whether PTEN loss as detected by quantitative fluorescence IHC (FIHC) predicts lethal disease outcomes after surgery for prostate cancer. DESIGN, SETTING AND PARTICIPANTS: We used formalin-fixed, paraffin-embedded radical prostatectomy specimens to construct tissue microarrays and perform dual FIHC for PTEN and AMACR for masking tumor epithelium, plus semi-quantitative multispectral imaging analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The association of PTEN status analyzed continuously and dichotomously (low [expression in the lowest quartile] vs higher [expression >lowest quartile]) with disease outcomes (metastasis and death) was assessed with adjustment for age, Gleason score, and stage in multivariable analyses. The prognostic ability of PTEN was assessed using logistic regression models. RESULTS AND LIMITATIONS: Low PTEN expression was associated with a higher risk of metastatic disease as both a continuous (hazard ratio [HR] 1.49, 95% confidence interval [CI] 1.14-1.92; p<0.003) and dichotomous (HR 1.92, 95% CI 1.02-3.63; p=0.04) variable. A significant association between low PTEN expression and poorer overall survival was observed (continuous: HR 1.89, 95% CI 1.37-2.63; p<0.001; dichotomous: HR 2.66, 95% CI 1.34-5.28; p=0.005). Addition of PTEN status to clinicopathologic factors (age, Gleason score, and stage) incrementally improved a prognostic model assessing 10-yr outcomes for metastatic disease (area under the curve [AUC] 0.76 vs 0.80) and death (AUC 0.70 vs 0.75). CONCLUSIONS: Low PTEN expression detected by FIHC in primary prostate cancer is an independent prognostic biomarker for metastatic disease and death after definitive therapy. FIHC for PTEN is a viable clinical diagnostic assay in this context. PATIENT SUMMARY: We looked at loss of the PTEN protein in prostate tumors from men treated with surgery. Men with PTEN loss were at higher risk of metastasis and death. Assessing PTEN status may be useful in better determination of the risk of poorer outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hamid AA, Gray KP, Huang Y, et al. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2018. PMID: 31411988. doi:10.1016/j.euo.2018.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。